{
    "clinical_study": {
        "@rank": "117549", 
        "acronym": "LenCombo", 
        "arm_group": {
            "arm_group_label": "Dose A", 
            "arm_group_type": "Experimental", 
            "description": "SAR650984 in combination with Lenalidomide"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To determine the maximum tolerated dose of SAR650984 with lenalidomide and dexamethasone in\n      patients with relapsed or refractory multiple myeloma.\n\n      Secondary Objectives:\n\n      To evaluate the safety, including immunogenicity, of SAR650984 in combination with\n      lenalidomide in relapse or refractory multple myeloma.  The severity, frequency and\n      incidence of all toxicities will be assessed.\n\n      To evaluate the pharmacokinetics (PK) of SAR650984 when administered in combination with\n      lenalidomide and the PK of lenalidomide in combination with SAR650984 and dexamethasone.\n\n      To assess the relationship between clinical (adverse event and/or tumor response) effects\n      and pharmacologic parameters (PK/pharmacodynamics), and/or biologic (correlative laboratory)\n      results.\n\n      Estimate the activity (response rate) using International Myeloma Working Group defined\n      response criteria of SAR650984 plus lenalidomide and low dose dexamethasone.\n\n      To describe overall survival, progression free survival (PFS) and time to disease\n      progression in patients treated with this combination."
        }, 
        "brief_title": "Phase 1 SAR650984 Combination With Lenalidomide", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study duration for an individual patient will include a screening period for inclusion\n      of up to 21 days, and at least 4 weeks of treatment in the absence of severe adverse\n      reaction, dose limiting toxicity or disease progression plus up to 60 days post-treatment\n      follow up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Male or female patients age 18 years or older.\n\n          -  Diagnosis of multiple myeloma & documentation of at least 2 prior therapies\n             (induction therapy is considered one prior therapy); there is no maximum number of\n             prior regimens & prior bone marrow transplant is acceptable.\n\n          -  Confirmed evidence of disease progression from immediately prior MM therapy or\n             refractory to the immediately prior therapy.\n\n          -  Patients may have received prior immunomodulatory drugs (IMiDs) (eg, lenalidomide or\n             thalidomide).\n\n          -  Patients with measurable disease.\n\n          -  Patients with a Karnofsky \u226560% performance status.\n\n          -  Females of childbearing potential (FCBP).\n\n          -  Voluntary written informed consent before performance of any study-related procedure\n             not part of routine medical care with the understanding that consent may be withdrawn\n             by the subject at any time without prejudice to future medical care.\n\n          -  Ability to understand the purpose and risks of the study & provide signed & dated\n             informed consent & authorization to use protected health information (in accordance\n             with national & local subject privacy regulations).\n\n          -  Able to take aspirin daily as prophylactic anti-coagulation therapy (patients\n             intolerant to aspirin may use warfarin, low molecular weight heparin or equivalent\n             anti-platelet therapy).\n\n          -  Adequate organ function.\n\n        Exclusion criteria:\n\n          -  Diagnosed or treated for another malignancy within 3 years prior to enrollment, with\n             the exception of complete resection of basal cell carcinoma or squamous cell\n             carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after\n             curative therapy.\n\n          -  Prior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, &\n             immunotherapy) within 21 days except for alkylating agents (eg, melphalan) where 28\n             days will be required or participated in another clinical trial during the past 30\n             days.\n\n          -  History of significant cardiovascular disease within the past 6 months, unless the\n             disease is well-controlled.\n\n          -  Prior peripheral stem cell transplant within 12 weeks of the first dose of study\n             treatment.\n\n          -  Daily requirement for corticosteroids (>10 mg/kg prednisone qd) (except for\n             inhalation corticosteroids).\n\n          -  Evidence of mucosal or internal bleeding.\n\n          -  Prior radiation therapy or major surgical procedure within 4 weeks of the first dose\n             of study treatment.\n\n          -  Known active infection requiring parenteral or oral anti-infective treatment.\n\n          -  Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or\n             confuse follow-up evaluation.\n\n          -  Any medical conditions that, in the Investigator's opinion, would impose excessive\n             risk to the patient.\n\n          -  Hypersensitivity to any of the components of study therapy that is not amenable to\n             premedication with steroids and H2 blockers.\n\n          -  Known human immunodeficiency virus (HIV) or active hepatitis B or C viral infection.\n\n          -  Neuropathy \u2265 Grade 3 or painful neuropathy \u2265 Grade 2.\n\n          -  Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral\n             medication, requirement for intravenous (IV) alimentation, active peptic ulcer or\n             prior surgical procedures or bowel resection affecting absorption.\n\n          -  Pregnancy.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749969", 
            "org_study_id": "TCD11863", 
            "secondary_id": "U1111-1119-3107"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose A", 
                "description": "Pharmaceutical form:solution Route of administration: intravenous", 
                "intervention_name": "SAR650984", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose A", 
                "description": "Pharmaceutical form:capsules Route of administration: oral", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lenalidomide", 
                "Thalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94117"
                    }, 
                    "name": "Investigational Site Number 840004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Investigational Site Number 840001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Investigational Site Number 840002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Investigational Site Number 840005"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Investigational Site Number 840003"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with adverse events when treated with SAR650984 in combination with Lenalidomide", 
            "safety_issue": "Yes", 
            "time_frame": "Up to one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749969"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Preliminary assessment of partial response", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Preliminary assessment of complete response", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Preliminary assessment of progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Preliminary assessment of survival", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Assessment of PK parameter - area under curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Assessment of PK parameter - maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Assessment of PK parameter - plasma half-life (T 1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Number of CD38 receptors occupied by SAR650984", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }, 
            {
                "measure": "Number of anti-SAR antibodies in response to SAR650984", 
                "safety_issue": "No", 
                "time_frame": "Up to one year"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}